S&P 500
7,673.51
-83.66
-1.08%
Dow
52,825.95
-30.14
-0.06%
Nasdaq
26,154.90
-547.96
-2.05%
NYSE Composite
24,188.88
-64.24
-0.26%
Russell 2000
2,776.36
-4.67
-0.17%
VIX
18.54
+1.86
+11.15%
MLTX · MoonLake Immunotherapeutics Class A Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
MoonLake Immunotherapeutics (MLTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$12.84
+2.19
(+20.56%)
● Market open
DAY'S RANGE
$12.84
$10.84
$13.31
52-WEEK RANGE
$12.84
$8.90
$23.29
What's happening
- MLTX is up 20.56% today, trading at $12.84. — Live quote
- Volume today (397,490) is well below its 3-month average of 1,495,400. (Finnhub fundamentals)
- Reports earnings on 2026-11-17 (before market open), 26 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.84 actual vs. $-0.94 estimated (+10.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 10
Hold 3
Sell 1
Strong sell 1
Aggregate ratings for 2026-10-01 (22 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MLTX
-19.20%
vs S&P 500
-32.57%
1-YEAR RETURN
MLTX
+16.27%
vs S&P 500
+1.10%
6-MONTH RETURN
MLTX
-41.93%
3-MONTH RETURN
MLTX
-43.77%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.84
Est. $-0.94
BEAT +10.4%
2026-04-26 (Q1 2026)
$-0.98
Est. $-0.91
MISS -7.7%
2026-01-26 (Q4 2025)
$-0.92
Est. $-1.01
BEAT +9.0%
2025-10-26 (Q3 2025)
$-1.10
Est. $-0.90
MISS -22.8%
Valuation Measures & Ratios
Enterprise Value4$528.0M
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)—
Price / Book73.69
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-82.68%
Return on Assets (ROA9)-58.17%
Avg Volume (3M)1,495,400
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.43B | $1.33B | $454.5M | $299.6M | $247.3M |
| P/E | -5.59 | -5.65 | -2.27 | -1.94 | -2.18 |
| Price/Book | 3.35 | 5.22 | 1.57 | 0.85 | 0.61 |
| EV/EBITDA | -4.05 | -4.56 | -0.80 | — | — |
| ROE | -59.89% | -92.35% | -69.32% | -43.77% | -27.80% |
| ROA | -44.68% | -58.60% | -48.34% | -33.65% | -22.16% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,048,665
Change from Prior Settlement-10.05%
% of Float—
Days to Cover (Short Ratio)4.23
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +16.3%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-09-30; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MLTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$61.7M | -$70.0M | -$71.4M | -$60.7M | -$47.5M | -$43.1M | -$30.6M | -$19.8M |
| Net income | -$61.8M | -$69.7M | -$69.7M | -$55.2M | -$39.9M | -$35.4M | -$24.3M | -$13.7M |
| EPS (diluted) | $-0.84 | $-0.98 | $-1.10 | $-0.87 | $-0.63 | $-0.56 | $-0.39 | $-0.22 |
| EPS (basic) | $-0.84 | $-0.98 | $-1.10 | $-0.87 | $-0.63 | $-0.56 | $-0.39 | $-0.22 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $573.9M | $400.4M | $424.4M | $414.3M | $460.1M | $511.3M | $477.9M | $518.2M |
| Total liabilities | $145.8M | $146.3M | $120.0M | $123.1M | $102.2M | $98.7M | $24.5M | $22.7M |
| Stockholders' equity | $428.2M | $254.0M | $304.5M | $288.9M | $353.7M | $407.5M | $446.8M | $488.2M |
| Total current assets | $570.0M | $396.6M | $421.7M | $411.2M | $455.5M | $506.3M | $474.3M | $512.3M |
| Total current liabilities | $45.4M | $46.1M | $45.5M | $48.4M | $27.4M | $24.0M | $22.5M | $20.1M |
| Cash & equivalents | $477.9M | $298.5M | $334.5M | $350.7M | $306.7M | $271.6M | $180.4M | $375.7M |
| Property, plant & equipment | $487.0K | $532.0K | $577.0K | $622.0K | $667.0K | $711.0K | $722.0K | $581.4K |
| Other non-current assets | $1.3M | $1.3M | $596.0K | $587.0K | $1.7M | $1.7M | $0 | — |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $99.5M | $99.0M | $74.1M | $73.7M | $73.4M | $73.0M | $0 | — |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$594.4M | -$532.6M | -$462.9M | -$400.5M | -$330.8M | -$275.5M | -$235.6M | -$190.0M |
| Accumulated other comprehensive income (loss) | $630.0K | $322.0K | $604.0K | $278.0K | $520.0K | $2.4M | $5.0M | $2.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$55.6M | -$66.3M | -$58.8M | -$44.5M | -$54.5M | -$38.1M | -$48.5M | -$25.3M |
| Investing cash flow | $322.0K | $98.0K | -$29.9M | $88.4M | $88.3M | $56.2M | -$147.3M | $58.3M |
| Financing cash flow | $234.6M | $30.6M | $72.4M | $480.0K | $0 | $73.1M | $151.0K | $183.0K |
| Free cash flow | -$55.6M | -$66.3M | -$58.8M | -$44.5M | -$54.5M | -$38.2M | -$48.6M | -$25.4M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $35.0K | $176.0K | $132.0K |
| Depreciation & amortization | $896.0K | $845.0K | $751.0K | $745.0K | $742.0K | $378.0K | $364.0K | $351.0K |
| Share-based compensation | $2.5M | $13.4M | $3.6M | $3.7M | $3.3M | $2.3M | $1.9M | $1.8M |
| Change in accounts payable | -$6.3M | -$6.2M | $4.3M | $8.2M | $5.1M | $3.0M | -$1.7M | $5.6M |
| Purchases of investments | $58.7M | $59.1M | $59.2M | $0 | $117.7M | $88.5M | $146.9M | $29.2M |
| Sales/maturities of investments | $59.1M | $59.2M | $29.3M | $88.4M | $205.9M | $144.8M | -$211.0K | $87.6M |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
| Debt issued | $0 | $24.5M | $0 | $0 | $0 | $73.0M | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$244.8M | -$143.1M | -$54.1M | -$65.1M | -$4.6M |
| Net income | -$227.3M | -$118.9M | -$36.0M | -$50.0M | -$4.5M |
| EPS (diluted) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | — |
| EPS (basic) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $424.4M | $477.9M | $526.5M | $76.8M | $9.7M |
| Total liabilities | $120.0M | $24.5M | $13.0M | $8.1M | $21.3M |
| Stockholders' equity | $304.5M | $446.8M | $495.7M | $48.9M | -$11.6M |
| Total current assets | $421.7M | $474.3M | $514.2M | $76.5M | $9.6M |
| Total current liabilities | $45.5M | $22.5M | $10.0M | $7.7M | $21.1M |
| Cash & equivalents | $334.5M | $180.4M | $451.2M | $39.5M | $8.0M |
| Property, plant & equipment | $577.0K | $722.0K | $320.9K | $49.4K | $45.7K |
| Other non-current assets | $596.0K | $0 | — | — | — |
| Accrued liabilities | — | — | — | — | $3.9M |
| Short-term debt | — | — | — | $0 | $15.0M |
| Long-term debt | $74.1M | $0 | — | — | — |
| Common stock & paid-in capital | — | — | — | — | $43 |
| Retained earnings | -$462.9M | -$235.6M | -$116.7M | -$80.7M | -$53.6M |
| Accumulated other comprehensive income (loss) | $604.0K | $5.0M | $2.4M | $350.9K | -$168.2K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$196.0M | -$116.6M | -$42.8M | -$55.9M | -$611.1K |
| Investing cash flow | $203.0M | -$205.6M | -$25.2M | -$32.3M | — |
| Financing cash flow | $146.0M | $51.3M | $479.7M | $119.7M | -$58.1K |
| Free cash flow | -$196.0M | -$117.1M | -$43.1M | -$55.9M | — |
| Capital expenditures | $35.0K | $520.0K | $284.0K | $16.0K | — |
| Depreciation & amortization | $2.6M | $1.4M | $370.0K | $164.8K | — |
| Share-based compensation | $12.9M | $7.3M | $7.1M | $9.7M | — |
| Change in accounts payable | $20.6M | $7.2M | $1.6M | -$1.3M | — |
| Purchases of investments | $265.4M | $350.3M | $175.7M | $42.2M | — |
| Sales/maturities of investments | $468.4M | $145.2M | $150.8M | $9.9M | — |
| Share repurchases | — | $50 | $0 | $0 | — |
| Debt issued | $73.0M | $0 | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MLTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers85.5%
Shares Outstanding73,915,296
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BVF INC/IL | 16,001,284 | $311.5M | 21.65% | +0.0% | 2026-08-14 |
| Deep Track Capital, LP | 6,999,025 | $136.3M | 9.47% | +9.2% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 4,280,624 | $83.3K | 5.79% | +0.0% | 2026-08-14 |
| D. E. Shaw & Co., Inc. | 3,365,507 | $65.5M | 4.55% | +40.8% | 2026-08-14 |
| Cormorant Asset Management, LP | 3,205,433 | $62.4M | 4.34% | -28.5% | 2026-08-14 |
| Jupiter Topco LLC | 3,085,906 | $60.1M | 4.17% | +0.0% | 2026-08-14 |
| Logos Global Management LP | 2,675,000 | $52.1M | 3.62% | +78.3% | 2026-08-14 |
| Weiss Asset Management LP | 2,581,813 | $50.3M | 3.49% | +51.1% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,972,893 | $38.4M | 2.67% | +49.0% | 2026-08-14 |
| TWO SIGMA INVESTMENTS, LP | 1,715,349 | $33.4M | 2.32% | +52.8% | 2026-08-07 |
| MPM BioImpact LLC | 1,606,967 | $31.3M | 2.17% | -11.3% | 2026-08-14 |
| Vivo Capital, LLC | 1,400,000 | $27.3M | 1.89% | +40.0% | 2026-08-14 |
| Jpmorgan Chase & Co | 1,386,422 | $27.6M | 1.88% | +27.4% | 2026-08-12 |
| Point72 Asset Management, L.P. | 1,158,732 | $22.6M | 1.57% | -15.3% | 2026-08-14 |
| BlackRock, Inc. | 1,094,791 | $21.3M | 1.48% | +7.1% | 2026-08-07 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,041,527 | $20.3K | 1.41% | -19.6% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 912,715 | $17.8M | 1.23% | -14.3% | 2026-08-13 |
| GREAT POINT PARTNERS LLC | 855,813 | $16.7M | 1.16% | +71.2% | 2026-08-14 |
| JANE STREET GROUP, LLC | 853,386 | $16.6M | 1.15% | +88.1% | 2026-08-14 |
| Candriam S.C.A. | 769,766 | $15.0M | 1.04% | -5.9% | 2026-08-13 |
| Bank Of America Corp /De/ | 751,897 | $14.6M | 1.02% | +3.7% | 2026-08-14 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 750,777 | $14.6M | 1.02% | +970.4% | 2026-08-13 |
| Trails Edge Capital Partners, LP | 750,000 | $14.6M | 1.01% | +0.0% | 2026-08-14 |
| HRT FINANCIAL LP | 679,244 | $13.2K | 0.92% | +39.3% | 2026-08-14 |
| RENAISSANCE TECHNOLOGIES LLC | 643,268 | $12.5M | 0.87% | +132.4% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-19 to 2026-07-27
Recent transactions
- Insiders have net sold 484,002 shares over the last 182 days, across 0 purchases and 15 sales.
- Most recent: Reich Kristian (Chief Scientific Officer) — Open market sale of 1,100 shares on 2026-07-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)484,002 sh(15 txns)
Net Shares-484,002
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer | Open market sale | 2026-07-27 | 1,100 |
| Santos da Silva Jorge | Chief Executive Officer | Open market sale | 2026-07-10 | 68,289 |
| Bodenstedt Matthias | Chief Financial Officer | Open market sale | 2026-06-22 | 39,120 |
| BVF PARTNERS L P/IL | Director | Open market sale | 2026-03-31 | 1,932,354 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-27 | Reich Kristian | Chief Scientific Officer | Open market sale | 1,100 | $20.00 |
| 2026-07-22 | Reich Kristian | Chief Scientific Officer | Open market sale | 2,448 | $20.00 |
| 2026-07-21 | Reich Kristian | Chief Scientific Officer | Open market sale | 50,000 | $20.02 |
| 2026-07-20 | Reich Kristian | Chief Scientific Officer | Open market sale | 43,700 | $20.09 |
| 2026-07-15 | Reich Kristian | Chief Scientific Officer | Open market sale | 16,105 | $20.01 |
| 2026-07-10 | Santos da Silva Jorge | Chief Executive Officer | Open market sale | 68,289 | $20.02 |
| 2026-07-09 | Santos da Silva Jorge | Chief Executive Officer | Open market sale | 33,936 | $20.01 |
| 2026-07-01 | Santos da Silva Jorge | Chief Executive Officer | Open market sale | 47,775 | $20.03 |
| 2026-06-22 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 39,120 | $22.04 |
| 2026-06-18 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 2,794 | $19.60 |
| 2026-06-17 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 15,082 | $19.68 |
| 2026-06-17 | Reich Kristian | Chief Scientific Officer | Open market sale | 50,000 | $19.43 |
| 2026-06-16 | Reich Kristian | Chief Scientific Officer | Open market sale | 50,000 | $18.70 |
| 2026-06-15 | Reich Kristian | Chief Scientific Officer | Open market sale | 50,000 | $18.89 |
| 2026-05-11 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 13,653 | $20.02 |
| 2026-04-14 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 2,426 | $19.56 |
| 2026-04-13 | Santos da Silva Jorge | Chief Executive Officer | Open market sale | 51,873 | $18.23 |
| 2026-04-10 | Santos da Silva Jorge | Chief Executive Officer | Open market sale | 98,127 | $18.41 |
| 2026-04-10 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 1,925 | $19.51 |
| 2026-04-09 | Bodenstedt Matthias | Chief Financial Officer | Open market sale | 85,870 | $18.94 |
| 2026-03-31 | BVF PARTNERS L P/IL | Director | Open market sale | 1,932,354 | $16.79 |
| 2026-03-31 | BVF PARTNERS L P/IL | Director | Open market sale | 1,569,116 | $16.79 |
| 2026-03-31 | BVF PARTNERS L P/IL | Director | Open market sale | 248,530 | $16.79 |
| 2026-01-07 | Bodenstedt Matthias | Chief Financial Officer | Grant / award | 354,296 | $0.00 |
| 2025-12-19 | Bodenstedt Matthias | Chief Financial Officer | Derivative conversion | 294,473 | — |
| 2025-12-19 | Bodenstedt Matthias | Chief Financial Officer | Disposition to issuer | 294,473 | — |
| 2025-12-19 | Reich Kristian | Chief Scientific Officer | Derivative conversion | 35,389 | — |
| 2025-12-19 | Reich Kristian | Chief Scientific Officer | Disposition to issuer | 35,389 | — |
| 2025-12-19 | Santos da Silva Jorge | Chief Executive Officer | Derivative conversion | 196,316 | — |
| 2025-12-19 | Santos da Silva Jorge | Chief Executive Officer | Disposition to issuer | 196,316 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 13:32 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-23 | 4 | 2026-07-21 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-20 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-15 | 8-K | 2026-07-14 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-22 | View on SEC.gov → |
Recent news
Headlines about MLTX (MoonLake Immunotherapeutics Class A Ordinary Shares). Links open the publisher — we don’t host full articles.
-
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
Benzinga · 2026-10-22 -
MLTX Nov 2026 12.000 put (MLTX261120P00012000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-22 -
MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains (NASDAQ:MLTX)
Seeking Alpha · 2026-10-20 -
MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains
SeekingAlpha · 2026-10-20 -
MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says
Seeking Alpha · 2026-10-18 -
MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says (MLTX:NASDAQ)
Seeking Alpha · 2026-10-18 -
MLTX Jan 2029 12.000 put (MLTX290119P00012000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
MLTX May 2027 5.000 put (MLTX270521P00005000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17
No headlines in this category right now — try “All”.